Fan Wu

Fan Wu is an associate in O’Melveny’s Beijing office and a member of Corporate Finance and Capital Markets Practice. Previously, Fan focuses her practice on intellectual property, especially on patent prosecution, trademark applications, post-grant proceedings, pre-litigation analysis, IP infringement, IP transaction and IP due diligence on behalf of domestic and foreign clients.

Capital Markets:

• Jenscare Scientific Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange

Intellectual Property:

• a global leading biopharma company on protecting the potential patent rights of its COVID-19 mRNA vaccine in mainland China, including providing advice on non-infringement and patentability
• a global leading food company on collaborating with local partners in China, especially providing advice on IP related issues
• a leading Singapore company in maternal and infant products industry, including providing advice on filing patent applications and patent infringement risks in China
• an affiliate of a reputable UK university on cooperating with Chinese local partners in research and development, especially on the IP related issues
• a UK pharmaceutical company on its collaboration with a CRO company in China, including providing advice on patent infringement risks
• a German private equity on its acquisition of Bock Germany particularly the Chinese aspects, including IP due diligence of trademarks, patents, and domain names
• a global leading daily necessity company on protecting its trademark rights in China, including providing advice on filing trademark applications, filing non-use cancellations against trademark registered by third parties, and potential trademark infringement risks
• a vitamin and nutrition beauty manufacturer on protecting its trademark rights in China, including providing advice on trademark applications, and fighting against potential infringers
• major and start-up companies, universities, and government departments on prosecuting patent applications mainly in biotechnological and pharmaceutical fields before CNIPA
• a global leading pharmaceutical company on defending the validity of its patents related to a vaccine before Reexamination and Invalidation Department of CNIPA and Beijing Intellectual Property Court
• a pharmaceutical company on analyzing the validity of a crystal form patent, and representing the client in invalidating the same before Reexamination and Invalidation Department of CNIPA
• a bio-tech company on prosecuting patents related to Antibody-Drug-Conjugate preparation method, and representing them in a freedom-to-operate analysis
• a company in dentistry on analyzing non-infringement and validity of a concerned patent related to dental implants, and representing the client in a freedom-to-operate analysis